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Background: The novel biolimus A9-coated stent (BA9) with a biodegradable polymer has shown efficacy in inhibiting neointimal proliferation 
compared to bare metal stents (BMS), and sustained safety in previous trials. However, whether the absence of a durable polymer in the BA9 maybe 
associated with complete stent strut coverage and improved long-term safety remains unknown. 
Methods: Between Nov/03-Mar/04, 48 pts with single de novo lesions were prospectively enrolled at one institution for percutaneous coronary 
intervention with BA9 (n=32) vs. BMS (n=16) as part of a randomized first-in-man study. Lesion criteria were vessels 2.75-4.00mm in diameter, 
and lesion length <24mm. By protocol, all pts were assigned for 6-mo. angiographic/intravascular ultrasound (IVUS) follow-up (FU). In addition, 
all eligible pts that did not experience major adverse cardiac events [MACE: cardiac death, myocardial infarction (MI), and target lesion 
revascularization (TLR)] during the FU period were contacted and re-consented for 6 yrs angiographic/IVUS and Optical Coherence Tomography 
(OCT). 
Results: Overall, mean age was 59 yrs, and 22% had diabetes. By quantitative coronary angiography (QCA), mean baseline lesion length (14.50mm 
vs. 12.75mm, p=ns) and reference diameter (2.95mm vs. 2.97mm, p=ns) were similar in BA9 and BMS groups, respectively. All lesions were 
successfully treated and there was no MACE during hospitalization. At 6-mo. FU, mean late lumen loss was 0.24mm in BA9 vs. 0.71mm in BMS, 
p<0.001; and there were no cases of incomplete stent apposition detected by IVUS. Clinical FU up to 5 yrs (100%) demonstrated 3 TLR (2 in BMS, 1 
in BA9), 2 cardiac deaths (1 in BMS, 1 in BA9), and absence of definite/probable stent thrombosis (ARC). At 6 yrs QCA/IVUS/OCT analysis (n=12, FU 
ongoing), preliminary observations demonstrated complete stent strut coverage and absence of “late catch-up” phenomenon in both groups. 
Conclusions: In this small single center experience, BA9 with a biodegradable polymer demonstrated favorable angiographic and IVUS results at 
mid-term FU and sustained safety and clinical efficacy in the long-term FU. Complete QCA, IVUS and OCT analysis at 6 yrs FU will be presented at the 
meeting.
